Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Valera, Elvira ^a   Mante, Michael ^a   Anderson, Scott ^a   Rockenstein, Edward ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Lenalidomide; Microgliosis; Neuroinflammation; Parkinson's disease

Indexed keywords

FRACTALKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; LENALIDOMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ALPHA SYNUCLEIN; CYTOKINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOLOGIC FACTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; GENE EXPRESSION; GLIOSIS; HIPPOCAMPUS; MICROGLIA; MOTOR DYSFUNCTION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; TRANSGENIC MOUSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; MENTAL DISORDERS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TRANSFORMED; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOLOGIC FACTORS; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; PARKINSON DISEASE; RNA, MESSENGER; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84930199829     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0320-x     Document Type: Article

References (68)

1. McKeith IG. Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. Neurol Clin. 2000;18(4):865-902.
2. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68(11):812-9. 10.1212/01.wnl.0000256715.13907.d3..
3. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol. 2006;19(6):572-9.
4. Dickson DW. Alpha-synuclein and the Lewy body disorders. Curr Opin Neurol. 2001;14(4):423-32.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-40. 10.1038/42166..
6. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am J Pathol. 1998;152(2):367-72.
7. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002;22(20):8797-807.
8. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, et al. A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem. 2005;280(36):31664-72.
9. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2012;14(1):38-48. 10.1038/nrn3406..
10. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108(10):4194-9. 10.1073/pnas.1100976108..
11. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem. 2010;113(5):1263-74. 10.1111/j.1471-4159.2010.06695.x..
12. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, Glabe C, et al. Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. Faseb J. 2011;25(1):326-36. 10.1096/fj.10-164624..
13. Lee SJ. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Molecular Neurosci: MN. 2008;34(1):17-22. 10.1007/s12031-007-0012-9..
14. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009;106(31):13010-5. 10.1073/pnas.0903691106..
15. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285(12):9262-72. 10.1074/jbc.M109.081125..
16. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005;19(6):533-42. 10.1096/fj.04-2751com..
17. Chesselet MF, Richter F, Zhu C, Magen I, Watson MB, Subramaniam SR. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics. 2012;9(2):297-314. 10.1007/s13311-012-0104-2..
18. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562. 10.1038/ncomms2534..
19. Beraud D, Maguire-Zeiss KA. Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S17-20. 10.1016/S1353-8020(11)70008-6..
20. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, et al. Alpha-synuclein alters Toll-like receptor expression. Front Neurosci. 2011;5:80. 10.3389/fnins.2011.00080..
21. Flood PM, Qian L, Peterson LJ, Zhang F, Shi JS, Gao HM, et al. Transcriptional factor NF-kappaB as a target for therapy in Parkinson's disease. Parkinsons Dis. 2011;2011:216298. 10.4061/2011/216298..
22. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177(6):1675-80.
23. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699-703.
24. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380-6.
25. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002;68(5):568-78. 10.1002/jnr.10231..
26. Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci. 2010;30(18):6236-46. 10.1523/JNEUROSCI.0567-10.2010..
27. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;27(2-3):229-37.
28. Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S, Kosberg K, et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther. 2014;22(10):1753-67. 10.1038/mt.2014.129..
29. Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, et al. Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. Cancer Chemother Pharmacol. 2012;69(4):943-7. 10.1007/s00280-011-1781-y..
30. Rozewski DM, Herman SE, Towns 2nd WH, Mahoney E, Stefanovski MR, Shin JD, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012;14(4):872-82. 10.1208/s12248-012-9401-2..
31. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem. 1996;39(17):3238-40. 10.1021/jm9603328..
32. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med. 1996;2(4):506-15.
33. Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. J Neurosci. 2014;34(28):9441-54. 10.1523/JNEUROSCI.5314-13.2014..
34. Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol. 2014;127(6):861-79. 10.1007/s00401-014-1256-4..
35. Halliday G. Clinicopathological aspects of motor parkinsonism. Parkinsonism Relat Disord. 2007;13 Suppl 3:S208-10. 10.1016/S1353-8020(08)70003-8..
36. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A. 1998;95(18):10896-901.
37. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia. 2002;37(4):314-27.
38. Sheridan GK, Murphy KJ. Neuron-glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage. Open Biol. 2013;3(12):130181. 10.1098/rsob.130181..
39. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9(7):917-24. 10.1038/nn1715..
40. Su X, Federoff HJ. Immune responses in Parkinson's disease: interplay between central and peripheral immune systems. BioMed Res Int. 2014;2014:275178. 10.1155/2014/275178..
41. Lee SJ, Desplats P, Lee HJ, Spencer B, Masliah E. Cell-to-cell transmission of α-synuclein aggregates. Methods Mol Biol. 2012;849:347-59. 10.1007/978-1-61779-551-0_23..
42. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV. Toll-like receptors in neurodegeneration. Brain Res Rev. 2009;59(2):278-92. 10.1016/j.brainresrev.2008.09.001..
43. Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W, Wenning GK. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol. 2011;179(2):954-63. 10.1016/j.ajpath.2011.04.013..
44. Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61(3):349-60. 10.1002/glia.22437..
45. Drouin-Ouellet J, St-Amour I, Saint-Pierre M, Lamontagne-Proulx J, Kriz J, Barker RA, et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Int J Neuropsychopharmacol. 2014. 10.1093/ijnp/pyu103..
46. Doty KR, Guillot-Sestier MV, Town T. The role of the immune system in neurodegenerative disorders: adaptive or maladaptive? Brain Res. 2014. 10.1016/j.brainres.2014.09.008..
47. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863-9. 10.1212/WNL.0b013e31820f2d79..
48. Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database Syst Rev. 2011;11:CD008454. 10.1002/14651858.CD008454.pub2..
49. Swiatkiewicz M, Zaremba M, Joniec I, Czlonkowski A, Kurkowska-Jastrzebska I. Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease. Pharmacol Reports. 2013;65(5):1227-36.
50. Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, et al. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol. 2012;237(2):318-34. 10.1016/j.expneurol.2012.06.025..
51. Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia. 2014;62(2):317-37. 10.1002/glia.22610..
52. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem. 2008;104(6):1504-25. 10.1111/j.1471-4159.2007.05087.x..
53. Martiniani R, Di Loreto V, Di Sano C, Lombardo A, Liberati AM. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol. 2012;2012:842945. 10.1155/2012/842945..
54. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033-45. 10.1007/s00262-008-0620-4..
55. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J. 2005;7(1):E14-9. 10.1208/aapsj070103..
56. Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, et al. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2009;220(1):191-7. 10.1016/j.expneurol.2009.08.028..
57. Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006;26(9):2467-73. 10.1523/JNEUROSCI.5253-05.2006..
58. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
59. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol. 2014;164(6):811-21. 10.1111/bjh.12708..
60. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-7. 10.3109/10428194.2012.728597..
61. Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther. 2004;4(12):1963-70. 10.1517/14712598.4.12.1963..
62. Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999;9(11):1625-30.
63. Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotrophic lateral sclerosis. 2009;10(5-6):393-404. 10.3109/17482960802709416..
64. Crystal SC, Leonidas J, Jakubowski A, Di Rocco A. Thalidomide induced acute worsening of Parkinson's disease. Mov Disord. 2009;24(12):1863-4. 10.1002/mds.22497..
65. Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE. Thalidomide-effect on T cell subsets as a possible mechanism of action. Int J Leprosy Mycobacterial dis. 1985;53(2):201-5.
66. Rocha NP, Scalzo PL, Barbosa IG, Souza MS, Morato IB, Vieira EL, et al. Cognitive status correlates with CXCL10/IP-10 levels in Parkinson's disease. Parkinsons Dis. 2014;2014:903796. 10.1155/2014/903796..
67. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol. 2002;178(1):13-20. 10.1006/exnr.2002.8019..
68. Kalkonde YV, Morgan WW, Sigala J, Maffi SK, Condello C, Kuziel W, et al. Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration. Brain Res. 2007;1128(1):1-11. 10.1016/j.brainres.2006.08.041..